Cost-Effectiveness Analysis of Etanercept in Combination with Methotrexate for Rheumatoid Arthritis - Markov Model Based on Data from Serbia

1. Tanaka Y. Current concepts in the management of rheumatoid arthritis. Korean J Intern Med. 2016;31(2):210-8.10.3904/kjim.2015.137477372926932398Search in Google Scholar

2. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016; (16)30173-8.Search in Google Scholar

3. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum. 2006;36(3):182-8.10.1016/j.semarthrit.2006.08.00617045630Search in Google Scholar

4. Sokka T, Kautiainen H, Pincus T, et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study. Arthritis Res Ther. 2010;12(2):R42.Search in Google Scholar

5. Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1316-22.10.1136/annrheumdis-2013-20462724550173Search in Google Scholar

6. Banal F, Dougados M, Combescure C, Gossec L. Sensitivity and specificity of the American College of Rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration: a systematic literature review and meta-analysis. Ann Rheum Dis. 2009;68(7):1184-9110.1136/ard.2008.09318718728049Search in Google Scholar

7. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-81.10.1002/art.2758420872595Open DOISearch in Google Scholar

8. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42(2):244-5710.1093/rheumatology/keg07212595618Search in Google Scholar

9. Bruce B, Fries JF. The Arthritis, Rheumatism and Aging Medical Information System (ARAMIS): still young at 30 years. Clin Exp Rheumatol. 2005;23(5Suppl 39): 163-7Search in Google Scholar

10. Schett G, Stach C, Zwerina J, Voll R, Manger B. How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum. 2008;58(10):2936-4811.10.1002/art.2395118821703Search in Google Scholar

11. Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev.2014 10;(6):CD000957.10.1002/14651858.CD000957.pub2704704124916606Search in Google Scholar

12. Tree Age Pro. Healthcare software. Tree Age Software Inc [release 2005, 1998-2005]. Available from: www.softscout.com/software/healthcare-and-Human Services/DiagnosisSearch in Google Scholar

13. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis. 2005;64(8):1174-9.10.1136/ard.2004.032789175559015708879Search in Google Scholar

14. St. Clair EW, Pisetsky DS, Haynes BF. Rheumatoid arthritis. Philadelphia: Lippincott Williams & Wilkins; 2004.Search in Google Scholar

15. Tariff book of health care services in health facilities of Republic of Serbia. Belgrade: Republic Institute for Health Insurance; 2008.Search in Google Scholar

16. The World Bank. Data and Statistics. Available from: hptt://web.worldbank.org./wbsite/external/datastatistics/0. [updated 2010 September 12].Search in Google Scholar

17. Drummond MF, Barbieri M, Wong JB. Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference? Med Decis Making. 2005;25(5):520-33.10.1177/0272989X0528056116160208Open DOISearch in Google Scholar

18. Weinstein MC, O’Brien B, Hornberger J, et al. ISPOR Task Force on Good Research Practices--Modeling Studies. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices—Modeling Studies. Value Health. 2003;6(1):9-1710.1046/j.1524-4733.2003.00234.xSearch in Google Scholar

19. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793-806.10.1002/art.22025Open DOISearch in Google Scholar

20. Combe B, Codreanu C, Fiocco U, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Ann Rheum Dis. 2009;68(7):1146-5210.1136/ard.2007.087106Search in Google Scholar

21. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88-96.10.1136/ard.2008.105197Search in Google Scholar

22. Nagy G, van Vollenhoven RF. Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now? Arthritis Res Ther. 2015;17:181.Search in Google Scholar

23. Klareskog L, van der Heijde D, de Jager JP, et al. TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675-81.10.1016/S0140-6736(04)15640-7Search in Google Scholar

24. Greenapple R. Trends in biologic therapies for rheumatoid arthritis: results from a survey of payers and providers. Am Health Drug Benefits. 2012;5(2):83-92.Search in Google Scholar

25. Howe A, Eyck LT, Dufour R, Shah N, Harrison DJ. Treatment patterns and annualdrug costs of biologic therapies across indications from the Humana commercial database. J Manag Care Spec Pharm. 2014;20(12):1236-44.Search in Google Scholar

26. Lambert CM. Medical therapy for rheumatoid arthritis--value for money? Rheumatology (Oxford). 2001;40(9):961-4.10.1093/rheumatology/40.9.96111561105Open DOISearch in Google Scholar

27. Kobelt G, Kasteng F. Access to innvative treatments in rheumatoid arthritis in Europe. A report prepared for the Europian Federation of Pharmaceutical Industry Associations (EFPIA); 2009Search in Google Scholar

28. Joensuu JT, Huoponen S, Aaltonen KJ, Konttinen YT, Nordström D, Blom M. The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review. PLoS One. 2015;10(3):e0119683.10.1371/journal.pone.0119683436359825781999Search in Google Scholar